Stockscreener 앱 받기
60.27
1.43%
-0.875
전일 마감가:
$61.15
열려 있는:
$60.96
하루 거래량:
719.51K
Relative Volume:
0.73
시가총액:
$2.04B
수익:
$55.63M
순이익/손실:
$-158.10M
주가수익비율:
-7.1578
EPS:
-8.4202
순현금흐름:
$-203.94M
1주 성능:
+7.18%
1개월 성능:
-14.66%
6개월 성능:
+22.60%
1년 성능:
+551.57%
1일 변동 폭
$59.09
$61.15
1주일 범위
$55.31
$61.51
52주 변동 폭
$8.27
$109.00
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
60.27 | 2.07B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 개시 | Wedbush | Neutral |
| 2026-03-17 | 개시 | TD Cowen | Buy |
| 2026-02-10 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
NKTR: 5,538 RSUs registered for resale via Morgan Stanley (NKTR) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Nektar Therapeutics: Shareholders Board Members Managers and Company Profile | US6402683063 - marketscreener.com
NKTR News | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Therapeutics (NKTR) Slips 1.5% Amid Consolidation Near Key Support LevelsFloat Adjusted Cap - newsline.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Is Nektar (NKTR) Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program? - simplywall.st
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility - Yahoo Finance
Inventory turnover of Nektar Therapeutics – XETR:ITH0 - TradingView
Nektar Therapeutics 8-K SEC Filing: Company Details, Common Stock, and NASDAQ Listing (June 2026) - Minichart
Diluted net income available to common stockholders of Nektar Therapeutics – XETR:ITH0 - TradingView
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Pullback - simplywall.st
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock - Insider Monkey
Nektar Therapeutics (NKTR) holders back plan share boost and auditor at 2026 meeting - Stock Titan
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits
NKTR: All proposals passed; immunology pipeline advances with REZPEG entering phase III trials - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - The National Law Review
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Drug developers outpace Nasdaq Bio, rezpeg data sends up Nektar - BioWorld News
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York - The AI Journal
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - AOL.com
Nektar Therapeutics to webcast at 2026 Jefferies Global Healthcare Conference on June 3 - Pluang
How to watch Nektar’s Jefferies healthcare fireside chat on June 3 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Interim CFO at Nektar Therapeutics (NKTR) files initial Form 3 ownership report - Stock Titan
Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data (NKTR) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial - simplywall.st
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - The Motley Fool
Prosight Management Increases Stake in Nektar Therapeutics - Intellectia AI
Nektar TherapeuticsCommon Stock (NQ: NKTR - The Chronicle-Journal
NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Therapeutics R&D chief sells $13,036 in shares - Investing.com UK
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics R&D chief sells $13,036 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares - Investing.com
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
넥타테라퓨틱스 주식 (NKTR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan | Chief R&D Officer |
May 19 '26 |
Sale |
65.51 |
199 |
13,036 |
20,975 |
| ROBIN HOWARD W | President & CEO |
May 19 '26 |
Sale |
65.51 |
444 |
29,086 |
75,045 |
1.27%
1.43%
자본화:
|
볼륨(24시간):